...
首页> 外文期刊>JALA: Journal of the Association for Laboratory Automation >Iridium Oxide Nanomonitors for Real-time Health Monitoring Systems
【24h】

Iridium Oxide Nanomonitors for Real-time Health Monitoring Systems

机译:用于实时健康监测系统的氧化铱纳米监测器

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

An innovative lab-on-a-chip device based on iridium oxide (IrOx) nanowires was designed, fabricated, and developed for real-time "point-of-care" diagnostics. The turnaround time in detection and the need for expensive equipment for analysis have considerably limited rapid and "point-of-care" diagnosis. This research demonstrates the potential of IrOx nanowires toward early disease diagnosis by detecting proteins that are disease markers. The device designed is based on electrical detection of protein biomarkers wherein a single capture immunoassay is built onto a vertically aligned IrOx nanowire platform. Detection of two inflammatory proteins, C-reactive protein (CRP) and myeloperoxidase (MPO) (Calbiochem, La Jolla, CA), that are biomarkers of cardiovascular diseases is demonstrated individually and concurrently. The performance metrics of the device in response to the two biomarkers in pure form and in serum samples were evaluated and compared with standard enzyme-linked immunosorbent assay (ELISA). The methodology that has been adopted is based on measuring real-time impedance changes because of the protein binding event through electrochemical impedance spectroscopy and calibrating its change in magnitude with concentration of proteins. We have demonstrated limit of detection up to 500 pg/mL for protein MPO and I ng/mL for CRP with cross-reactivity of less than 8% of selective binding of these two inflammatory biomarkers. (JALA 2009;14:400-6)
机译:设计,制造和开发了一种基于氧化铱(IrOx)纳米线的创新芯片实验室设备,用于实时“即时护理”诊断。检测的周转时间和对昂贵分析设备的需求已大大限制了快速和“即时诊断”诊断。这项研究通过检测作为疾病标志物的蛋白质,证明了IrOx纳米线在早期疾病诊断中的潜力。设计的设备基于蛋白质生物标志物的电检测,其中将单次捕获免疫测定构建在垂直对齐的IrOx纳米线平台上。分别和同时证明了检测两种炎症蛋白,即C反应蛋白(CRP)和髓过氧化物酶(MPO)(Calbiochem,La Jolla,CA),它们是心血管疾病的生物标志物。评估了设备对纯生物形式和血清样品中的两种生物标志物的反应性能指标,并与标准酶联免疫吸附测定(ELISA)进行了比较。已采用的方法基于通过电化学阻抗谱测量因蛋白质结合事件而引起的实时阻抗变化,并校准其随蛋白质浓度的大小变化。我们已经证明蛋白质MPO的检测限高达500 pg / mL,CRP的检测限高达1 ng / mL,交叉反应性低于这两种炎症生物标记物选择性结合的8%。 (JALA 2009; 14:400-6)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号